FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors - October 24, 2023
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, October 24, 2023, CDER's Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors. This presentation will focus on the importance of medications used for opioid use disorder and provide an overview of FDA's postmarket surveillance process related to medication errors. The presenters will discuss medication errors identified for naltrexone injectable suspension, actions to mitigate those errors, and will highlight the importance of the healthcare provider's role in drug safety.
Register Here: FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors
Activity Outline and Continuing Education Information